Skip to main content

Blavatnik Fund button The Blavatnik Fund for Innovation at Yale

The Blavatnik Fund for Innovation at Yale, made possible by a generous grant from the Blavatnik Family Foundation, supports Yale faculty in the commercialization of applied research and technology in the life sciences. A significant obstacle to the development of early-stage university discoveries is the lack of funding for the proof-of-concept and validation studies needed to demonstrate commercial potential. To overcome this barrier, the Fund provides funding and business development support to help validate nascent technologies and identify potential industry partners to advance these technologies to the marketplace. 

The Fund seeks to support innovative, investigator-initiated research aimed at extending preliminary observations, with proof-of-concept and the generation of robust intellectual property as key objectives. The Fund is designed to accommodate projects of varying magnitude, as appropriate. Its primary goal is to advance technologies to the point where additional support from industry and/or technology transfer is achieved.  Supported projects may include such areas as therapeutics, diagnostics/biomarkers, medical devices, or research instruments, among others. 

The expected goal of completed projects will be partnerships with industry, through licenses to existing biopharmaceutical companies and startup firms (some launched from the Fund-supported technology) or via major industry-sponsored research agreements. It is expected that these alliances will lead to additional industry-sponsored research support. The Fund is structured as a sustainable, “evergreen” program.  A percentage of the revenue from successfully licensed technologies will be contributed back to the Blavatnik Fund for Innovation at Yale to support ongoing and future projects. 

The Fund and the progress of its supported projects are managed by the Office of Cooperative Research (OCR) under the auspices of the Office of the Provost, in consultation with an independent Investment Advisory Board comprising leaders from the various sectors of the business and investment community.